Ophthalmology Research Today is a free monthly online journal that collates and summarizes the latest research about Ophthalmology, including details on eye surgery, myopia, cataracts.

Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.

Abelson MB, Gomes PJ

Schepens Eye Research Institute, Boston, Massachusetts, USA abelson@vision.eri.harvard.edu.

Background: Olopatadine 0.2% is the first topical ophthalmic antihistamine/mast cell stabilizer indicated for once-daily dosing. Objective: This review provides a comprehensive description of the pharmacology of the olopatadine molecule, as well as of the clinical efficacy, tolerability, and safety of olopatadine 0.2% ophthalmic solution. Methods: References cited in this review were obtained from the PubMed biomedical literature database. Also included were several posters presented at nationally renowned ophthalmology-related conferences. Results/conclusion: Olopatadine 0.2% was found to be a safe and effective medication for the reduction of itching with a duration of action of up to 24 h. The added convenience of a once-a-day dosing regimen is a major advancement in this drug class.

Published 24 April 2008 in Expert Opin Drug Metab Toxicol, 4(4): 453-61.
Full-text of this article is available online (may require subscription).

© 2005-2008 Ophthalmology Research Today. All Rights Reserved.